Technology | Advanced Visualization | January 06, 2017

SyntheticMR Introduces REMyDI for Automatic Measurement of Myelin Volume

Feature of SyMRI software performs full quantitative volume measurement in a single 5-6 minute scan

SyntheticMR, MRI software, SyMRI, REMyDI, automatic myelin volume measurement, RSNA 2016

January 6, 2017 — SyntheticMR AB introduced REMyDI for automatic quantification of myelin volume in the brain at the 2016 annual meeting of the Radiological Society of North America (RSNA) in November. Easy quantification of myelin allows clinicians to follow myelination in the developing brain and monitor myelin degeneration in patients with demyelinating and neurodegenerative disorders. REMyDI is a feature of the SyMRI post-processing software from SyntheticMR.

Measuring myelin volume with conventional magnetic resonance imaging (MRI) is challenging. With the REMyDI feature in SyMRI, clinicians can now get an automatic volume measurement of myelin from a single 5-6 minute quantitative MRI scan. The automatic post-processing is completed in less than 10 seconds.

"The advantage of retrieving a myelin estimation from a quantitative MR sequence that can also provide relaxometry-based volumetry and multiple contrasts is that a large amount of information is collected using a single, six-minute long acquisition. At Karolinska we have used REMyDI in studies of MS-patients and patients with neurodegenerative diseases,” said Tobias Granberg, M.D., Ph.D., Karolinska University Hospital, Sweden."

The REMyDI feature is available in the SyMRI Research Edition package and will be available for clinical use in the SyMRI Neuro package in 2017.

SyMRI is compatible with MR scanners from leading vendors and was demonstrated in the booths of SyntheticMR’s partners at RSNA. SyMRI is a CE-marked product and is U.S. Food and Drug Administration (FDA) 510(k) pending.

For more information: www.syntheticmr.com

Related Content

Gadolinium based contrast dye in brain MRI

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | January 17, 2020
January 17, 2020 — Bracco Diagnostics Inc., the U.
Carestream’s X-ray digital tomosynthesis functionality creates three-dimensional datasets from digital radiography (DR) that can be scrolled through similar to computed tomography (CT) imaging. It received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in January 2020. Digital tomosynthesis uses a single sweep of X-ray exposures and streamlines operator workflow by separating the process of DT exposure acquisition from image volume formation.
News | Digital Radiography (DR) | January 15, 2020
January 15, 2020 — Carestream’s X-ray digital tomosynthesis (DT) functionality, which creates three-dimensional datas
MR Solutions cryogen free preclinical MRI
News | Magnetic Resonance Imaging (MRI) | January 09, 2020
January 9, 2020 — MR Solutions is continuing to expand its support network
prostate cancer UCL study
News | Prostate Cancer | January 03, 2020
January 3, 2020 — Nearly one in six deaths from...
Videos | Advanced Visualization | December 30, 2019
This is a hologram of a fracture from a...
Videos | MRI Breast | December 26, 2019
Gillian Newstead, M.D., director of global breast imaging and former professor at the University of Chicago, explains
Feinstein Institutes' Thomas Chaly, Ph.D., poses in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s

Feinstein Institutes' Thomas Chaly, Ph.D., in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s

News | Nuclear Imaging | December 26, 2019
December 26, 2019 — The Feinstein Institutes for Medical R...